
Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.

Learn about patient concerns in EoE and the benefits of adequate monitoring and effective maintenance therapy on disease control and QoL

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares highlights the substantial impact of type 2 inflammatory diseases on the quality of life of patients and their caregivers.
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.

Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.
Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Embark on this interactive triathlon challenge to uncover the interplay of type 2 inflammation, barrier dysfunction, and neuroimmune dysregulation in the disease pathology of CRSwNP.
Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.